Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

PRX 00023

Known as: PRX-00023, PRX00023 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
To address the development of early anxiety disorders across the lifespan, the High USV line of rats was bred based on rates of… Expand
Is this relevant?
2008
2008
PRX-00023, a serotonin 1A receptor agonist, was designed to provide high potency and selectivity for its target. To assess the… Expand
Is this relevant?
2008
2008
BACKGROUND The serotonin 1A (5-hydroxytryptamine 1A [5-HT1A]) receptor likely plays a critical role in anxiety pathophysiology… Expand
  • table II
Is this relevant?
2007
2007
PRX-00023 is a novel, nonazapirone 5-HT1A agonist in clinical development for treatment of affective disorders. The objectives of… Expand
Is this relevant?
Review
2007
Review
2007
  • Tomas de Paulis
  • Current opinion in investigational drugs
  • 2007
  • Corpus ID: 35371886
EPIX Pharmaceuticals Inc (formerly Predix Pharmaceuticals Inc) is developing PRX-00023, an oral aryl piperazine 5-HT1A agonist… Expand
Is this relevant?
Highly Cited
2006
Highly Cited
2006
We report the discovery of a novel, potent, and selective amidosulfonamide nonazapirone 5-HT1A agonist for the treatment of… Expand
Is this relevant?
2006
2006
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the… Expand
Is this relevant?
2005
2005
  • 2005
  • Corpus ID: 195160372
 
Is this relevant?